NCT07073703 Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
| NCT ID | NCT07073703 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Bladder (Urothelial, Transitional Cell) Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 106 participants |
| Start Date | 2025-12-03 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 106 participants in total. It began in 2025-12-03 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer. In older patients, common co-morbidities include fatigue, physical deconditioning characterized by reduced cardiorespiratory fitness and progressing sarcopenia, pain- whether disease- related or treatment-induced- and undernutrition. These factors increased the risk of post-operative complications and exacerbate patient frailty. The investigators propose a personalized 6-month program both pre- and post-surgery, including adapted physical activity sessions, therapeutic education workshops, and systematic referral to the department's DAPAP program.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of bladder or kidney cancer * Surgical treatment * No severe cognitive impairment preventing understanding of the protocol * Affiliated or entitled to a social security scheme * Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study Exclusion Criteria: * Surgery already done * Significant co-morbidities that contraindicate physical activity: associated cardiac pathologies, respiratory pathologies, disabling joint pathologies, etc. * Deprived of liberty or under guardianship * Benefiting from a prehabilitation prescription with a private physiotherapist.
Contact & Investigator
David HUPIN, MD
PRINCIPAL INVESTIGATOR
CHU de Saint Etienne
Frequently Asked Questions
Who can join the NCT07073703 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Bladder (Urothelial, Transitional Cell) Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07073703 currently recruiting?
Yes, NCT07073703 is actively recruiting participants. Contact the research team at evolene.fayolle@chu-st-etienne.fr for enrollment information.
Where is the NCT07073703 trial being conducted?
This trial is being conducted at Saint-Etienne, France, Saint-Etienne, France.
Who is sponsoring the NCT07073703 clinical trial?
NCT07073703 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is David HUPIN, MD at CHU de Saint Etienne. The trial plans to enroll 106 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.